Mark DürkopProject Lead at University of Natural Resources and Life Sciences
With more than nine years of experience, Mark is a passionate scientist in the field of biopharmaceutical process development. He worked together with Novartis and Boehringer-Ingelheim targeting their needs in process development and understanding. Together with his team, he is developing a QbD software for both up and downstream processes. This software utilizes process data and first principle models (hybrid models) to quickly predict critical quality attributes (CQAs) from critical process parameters (CPPs). Hereby, bioprocess development and characterization will be accelerated significantly while simultaneously a better process understanding is gathered. From this research project the company “Novasign” was founded in 2019 offering this unique software solution.